Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp had 109 analyst reports since July 30, 2015 according to SRatingsIntel. The company was reinitiated on Monday, August 10 by Credit Suisse. The rating was initiated by UBS on Tuesday, September 22 with “Buy”. RBC Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Sunday, November 5. RBC Capital Markets has “Buy” rating and $130.0 target. The rating was maintained by Jefferies on Thursday, February 1 with “Buy”. The firm has “Buy” rating by Jefferies given on Friday, May 26. The stock has “Buy” rating by Cowen & Co on Tuesday, March 20. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, October 26. Cowen & Co initiated the stock with “Outperform” rating in Friday, October 9 report. The firm has “Buy” rating given on Wednesday, July 27 by BTIG Research. Barclays Capital maintained Edwards Lifesciences Corporation (NYSE:EW) rating on Wednesday, July 27. Barclays Capital has “Equalweight” rating and $115 target. See Edwards Lifesciences Corporation (NYSE:EW) latest ratings:
10/04/2018 Broker: SunTrust Rating: Buy New Target: $180.0000 Maintain
22/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $174.0 Maintain
20/03/2018 Broker: Cowen & Co Rating: Buy New Target: $165.0 Maintain
15/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $174.0 Maintain
02/02/2018 Broker: Guggenheim Rating: Buy New Target: $162.0 Maintain
01/02/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $155.0 Maintain
02/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $135 New Target: $140 Maintain
02/02/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $135 New Target: $155 Maintain
02/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $140.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $150.0 Maintain
Origin Asset Management Llp increased Apple Inc (AAPL) stake by 71.73% reported in 2017Q4 SEC filing. Origin Asset Management Llp acquired 116,800 shares as Apple Inc (AAPL)’s stock declined 3.81%. The Origin Asset Management Llp holds 279,630 shares with $47.32M value, up from 162,830 last quarter. Apple Inc now has $833.71B valuation. The stock decreased 0.85% or $1.41 during the last trading session, reaching $164.31. About 25.56 million shares traded. Apple Inc. (NASDAQ:AAPL) has risen 19.49% since April 23, 2017 and is uptrending. It has outperformed by 7.94% the S&P500.
Since December 7, 2017, it had 0 insider purchases, and 5 insider sales for $26.72 million activity. Riccio Daniel J. sold $2.65 million worth of stock. The insider Maestri Luca sold $6.83M. SCHILLER PHILIP W had sold 69,491 shares worth $11.56M.
Among 54 analysts covering Apple Inc. (NASDAQ:AAPL), 35 have Buy rating, 1 Sell and 18 Hold. Therefore 65% are positive. Apple Inc. had 400 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Buy” rating and $200.0 target in Monday, January 15 report. As per Wednesday, September 13, the company rating was maintained by Bernstein. The firm earned “Neutral” rating on Monday, January 22 by Atlantic Securities. The rating was maintained by Pacific Crest with “Positive” on Monday, August 17. The stock of Apple Inc. (NASDAQ:AAPL) earned “Buy” rating by CLSA on Friday, September 16. Maxim Group upgraded the shares of AAPL in report on Friday, October 23 to “Buy” rating. Bernstein maintained the shares of AAPL in report on Monday, June 12 with “Buy” rating. The stock of Apple Inc. (NASDAQ:AAPL) has “Outperform” rating given on Thursday, September 22 by RBC Capital Markets. On Monday, August 7 the stock rating was maintained by Drexel Hamilton with “Buy”. The firm has “Buy” rating by UBS given on Tuesday, September 12.
Origin Asset Management Llp decreased Aetna Inc New (NYSE:AET) stake by 5,700 shares to 186,033 valued at $33.56M in 2017Q4. It also reduced Alphabet Inc stake by 1,300 shares and now owns 39,524 shares. Amgen Inc (NASDAQ:AMGN) was reduced too.
Investors sentiment increased to 0.73 in 2017 Q4. Its up 0.03, from 0.7 in 2017Q3. It increased, as 50 investors sold AAPL shares while 1023 reduced holdings. 151 funds opened positions while 637 raised stakes. 2.98 billion shares or 0.18% more from 2.97 billion shares in 2017Q3 were reported. Holowesko Prtn Limited stated it has 412,500 shares or 4.41% of all its holdings. Legacy Private stated it has 30,382 shares. 140 were accumulated by Weitz Inv Mngmt. Moreover, Balyasny Asset Mngmt Ltd Liability Com has 0.07% invested in Apple Inc. (NASDAQ:AAPL). First Foundation Advisors invested in 0.87% or 95,229 shares. Brookstone Capital Mngmt holds 0.27% of its portfolio in Apple Inc. (NASDAQ:AAPL) for 17,550 shares. North Star Inv Mgmt Corporation, Illinois-based fund reported 98,777 shares. Mcdaniel Terry And reported 1.58% stake. Lipe Dalton has invested 4.18% in Apple Inc. (NASDAQ:AAPL). Financial Ptnrs Cap Mgmt Ltd Liability Co reported 0.12% stake. Valmark Advisers owns 19,272 shares or 0.07% of their US portfolio. Country Trust Comml Bank reported 4.31% stake. Condor Cap Mgmt has invested 1.69% in Apple Inc. (NASDAQ:AAPL). Orleans Cap Corp La has 2.95% invested in Apple Inc. (NASDAQ:AAPL) for 24,492 shares. North Star Asset Mgmt Inc has 1.77% invested in Apple Inc. (NASDAQ:AAPL).
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $28.83 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 50.72 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.